CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Letrozole

来曲唑 杂质对照品Letrozole Impurities

25 个杂质条目25 impurity entries

本页汇总 来曲唑 的 25 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 25 impurity reference standards of Letrozole. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 来曲唑(Letrozole)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesStability-indicating spectrophotometric manipulations for the determination of Letrozole in the presence of its alkali-induced degradation products; towards whiteness and ChlorTox scale perspectives
    BMC chemistry · 2025 · El-Fatah NAA et al.  ·  PMID 40057722  ·  DOI
  2. 杂质研究Impurity studiesIdentification of related substances in letrozole using LC-Q-TOF/MS
    Journal of pharmaceutical and biomedical analysis · 2025 · Hu ZL et al.  ·  PMID 40479786  ·  DOI
  3. 杂质研究Impurity studiesPreparation and characterization of two new forced degradation products of letrozole and development of a stability-indicating RP-LC method for its determination
    Pakistan journal of pharmaceutical sciences · 2015 · Elkady EF, Fouad MA  ·  PMID 26639498
  4. 分析方法Analytical MethodsDevelopment and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment
    Pharmaceuticals (Basel, Switzerland) · 2022 · Turković L et al.  ·  PMID 35631440  ·  DOI
  5. 分析方法Analytical MethodsSimultaneous quantification of abemaciclib and letrozole in rat plasma: method development, validation and pharmacokinetic application
    Biomedical chromatography : BMC · 2020 · Dhakne P et al.  ·  PMID 32166756  ·  DOI

来曲唑 —— 原料药与杂质对照品Letrozole — drug substance & impurities

共 25 个条目(含原料药本体)25 items incl. the drug substance
Letrozole Impurity 1 structure
1
来曲唑杂质1Letrozole Impurity 1
Letrozole Impurity 1
CAS No.112809-52-6
Chemical FormulaC17H11N5
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 2 structure
2
来曲唑杂质2Letrozole Impurity 2
Letrozole Impurity 2
CAS No.113402-31-6
Chemical FormulaC22H13N3
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 3 structure
3
来曲唑杂质3Letrozole Impurity 3
Letrozole Impurity 3
CAS No.112809-25-3
Chemical FormulaC10H8N4
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 4 structure
4
来曲唑杂质4Letrozole Impurity 4
Letrozole Impurity 4
CAS No.28188-41-2
Chemical FormulaC8H6BrN
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 8 structure
8
来曲唑杂质8Letrozole Impurity 8
Letrozole Impurity 8
CAS No.403-54-3
Chemical FormulaC7H4FN
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 9 structure
9
来曲唑杂质9Letrozole Impurity 9
Letrozole Impurity 9
CAS No.394-47-8
Chemical FormulaC7H4FN
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 10 structure
10
来曲唑杂质10Letrozole Impurity 10
Letrozole Impurity 10
CAS No.128-08-5
Chemical FormulaC4H4BrNO2
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 11 structure
11
来曲唑杂质11Letrozole Impurity 11
Letrozole Impurity 11
CAS No.123-56-8
Chemical FormulaC4H5NO2
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 15 structure
15
来曲唑杂质15Letrozole Impurity 15
Letrozole Impurity 15
CAS No.148992-02-3
Chemical FormulaC16H12N4
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 17 structure
17
来曲唑杂质17Letrozole Impurity 17
Letrozole Impurity 17
CAS No.32446-66-5
Chemical FormulaC15H8N2O
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 21 structure
21
来曲唑杂质21Letrozole Impurity 21
Letrozole Impurity 21
CAS No.1644566-39-1
Chemical FormulaC17H13N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 22 structure
22
来曲唑杂质22Letrozole Impurity 22
Letrozole Impurity 22
CAS No.2170106-13-3
Chemical FormulaC17H15N5O2
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 23 structure
23
来曲唑杂质23Letrozole Impurity 23
Letrozole Impurity 23
CAS No.2500927-47-7
Chemical FormulaC17H13N5O
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 24 structure
24
来曲唑杂质24Letrozole Impurity 24
Letrozole Impurity 24
CAS No.305861-48-7
Chemical FormulaC12H9N7
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 26 structure
26
来曲唑杂质26Letrozole Impurity 26
Letrozole Impurity 26
CAS No.107759-58-0
Chemical FormulaC23H35NO4Sn
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 27 structure
27
来曲唑杂质27Letrozole Impurity 27
Letrozole Impurity 27
CAS No.1194-02-1
Chemical FormulaC7H4FN
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 28 structure
28
来曲唑杂质28Letrozole Impurity 28
Letrozole Impurity 28
CAS No.134521-16-7
Chemical FormulaC15H10N2O
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 29 structure
29
来曲唑杂质29Letrozole Impurity 29
Letrozole Impurity 29
CAS No.143030-54-0
Chemical FormulaC16H11BrN4
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 31 structure
31
来曲唑杂质31Letrozole Impurity 31
Letrozole Impurity 31
CAS No.10466-37-2
Chemical FormulaC15H10N2
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 32 structure
32
来曲唑杂质32Letrozole Impurity 32
Letrozole Impurity 32
CAS No.17201-43-3
Chemical FormulaC8H6BrN
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 33 structure
33
来曲唑杂质33Letrozole Impurity 33
Letrozole Impurity 33
CAS No.124484-32-8
Chemical FormulaC6H6N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 34 structure
34
来曲唑杂质34Letrozole Impurity 34
Letrozole Impurity 34
CAS No.2600729-46-0
Chemical FormulaC6H6N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 35 structure
35
来曲唑杂质35Letrozole Impurity 35
Letrozole Impurity 35
CAS No.19611-63-3
Chemical FormulaC5H4N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 38 structure
38
来曲唑杂质38Letrozole Impurity 38
Letrozole Impurity 38
CAS No.3566-61-8
Chemical FormulaC8H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Letrozole Impurity 39 structure
39
来曲唑杂质39Letrozole Impurity 39
Letrozole Impurity 39
CAS No.112809-27-5
Chemical FormulaC10H8N4
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

来曲唑 —— 研究文献与合成路线Letrozole — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 来曲唑 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Letrozole. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Preparation and characterization of two new forced degradation products of letrozole and development of a stability-indicating RP-LC method for its determination
    Elkady EF, Fouad MA · Pakistan journal of pharmaceutical sciences · 2015 · 被引 4cited 4
  2. Stability-indicating spectrophotometric manipulations for the determination of Letrozole in the presence of its alkali-induced degradation products; towards whiteness and ChlorTox scale perspectives
    El-Fatah NAA, Fouad MM, Hegazy MA, et al. · BMC chemistry · 2025
  3. Interaction of letrozole and its degradation products with aromatase: chemometric assessment of kinetics and structure-based binding validation
    De Luca M, Occhiuzzi MA, Rizzuti B, et al. · Journal of enzyme inhibition and medicinal chemistry · 2022 · 被引 10cited 10
  4. Stability-indicating liquid chromatographic method for the determination of Letrozole in pharmaceutical formulations
    Annapurna MM, Mohapatro C, Narendra A · Journal of pharmaceutical analysis · 2012 · 被引 16cited 16
  5. Spectrophotometric methods for the determination of letrozole in bulk and pharmaceutical dosage forms
    Acharjya SK, Mallick P, Panda P, et al. · Journal of advanced pharmaceutical technology & research · 2010 · 被引 18cited 18
  6. Synthesis and characterization of poly[1-(N,N-bis-carboxymethyl)amino-3-allylglycerol-co-dimethylacrylamide] grafted to magnetic nano-particles for extraction and determination of letrozole in biological and pharmaceutical samples
    Ahmad Panahi H, Soltani ER, Moniri E, et al. · Talanta · 2013 · 被引 12cited 12

合成与制备工艺专利Synthesis & process patents

  1. REGIOSELECTIVE SYNTHESIS OF LETROZOLE
    GORE VINAYAK GOVIND, SHUKLA VINAY KUMAR, BHANDARI SHERYAS, HASBE SURESH, et al. · 公开号 WO2010146391WO2010146391 · 2010
  2. PROCESS AND INTERMEDIATE OF LETROZOLE
    VISHNUKANT B · 公开号 WO2009078036WO2009078036 · 2009
  3. PROCESS FOR THE PREPARATION OF LETROZOLE
    HAIDER HUSSAIN, SOLANKI KIRTIPALSINH SAIJANSINH, PAL GAUTAM, SINGH MANOJ KUMAR, et al. · 公开号 EP1945618EP1945618 · 2008
  4. PROCESS FOR THE PREPARATION OF LETROZOLE
    HAIDER HUSSAIN, SOLANKI KIRTIPALSINH SAIJANSINH, PAL GAUTAM, SINGH MANOJ KUMAR, et al. · 公开号 WO2007054964WO2007054964 · 2007
  5. PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES
    SHRAWAT VIMAL KUMAR, SINGH JAI PAL, NAUTIYAL RAJESH PRASAD · 公开号 US2010234617US2010234617 · 2010

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

来曲唑 杂质谱研究要点Letrozole — impurity profiling notes

下面这些是拿到 来曲唑 的 25 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 25 impurity entries for Letrozole, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances